The impact of COVID19 on drug development and the future of clinical trials
E-session 530002
Expert
/attachment.e-eso.net%2F48%2Fdc7fffe1-0279-476c-a375-5311e867ab4e.jpg)
CHUM- Notre Dame Hospital
Montreal, Canada
Montreal, Canada
Expert
/attachment.e-eso.net%2F48%2Fbd1f84dc-20e3-455c-938f-b6c47f0b313e.jpg)
Clinical Professor and Head, Medical Oncology
Tom Baker Cancer Center
Calgary, Canada
Tom Baker Cancer Center
Calgary, Canada
Expert
/attachment.e-eso.net%2F48%2Fcbb181f0-7e89-482b-9db7-86cff1eb01c1.jpg)
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
Bellinzona, Switzerland
Discussant
/attachment.e-eso.net%2F48%2F2021031908395615.jpg)
Substantive Consultant Medical Oncologist
Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
This e-Session is part of the following pathway(s):
08
Jun 2020
